| Heading: |
Restless Legs Syndrome: Medical Treatments |
| Question ID: |
1808329 |
| UIN: |
56598 |
| House: |
Commons |
| Date tabled: |
2025-06-02 |
| Asking Member ID: |
5121 |
| Asking Member display name: |
Henry Tufnell
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Henry Tufnell
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he made of the use of dopamine agonists as a first-line treatment for restless legs syndrome (RLS) before the NICE guidance was updated in February 2025; and what steps he is taking |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-06-05 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
No assessment has been made. The National Institute for Health and Care Excellence has not developed any guidelines on the diagnosis and/or management of restless leg syndrome (RLS) but has commissioned a Clinical Knowledge Summary (CKS) on the diagnosis ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |